EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Locking CBL TKBD in its native conformation presents a novel therapeutic opportunity in mutant CBL-dependent leukemia

Syed Feroj Ahmed, Jayanthi Anand, Wei Zhang, Lori Buetow, Loveena Rishi, Louise Mitchell, Jonathan Bohlen, Sergio Lilla, Gary J Sibbet, Colin Nixon, Amrita Patel, Karolina A Majorek und 5 weitere

Molecular Therapy · 2025

DOI: 10.1016/j.ymthe.2025.04.042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Syed Feroj Ahmed und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-cbl, Mutation, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Glasgow Children's Hospital Charity, Cancer Research UK Beatson Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Casitas B-lineage lymphoma (CBL) is an E3 ubiquitin ligase critical for negatively regulating receptor protein tyrosine kinases (RTKs). Deleterious CBL mutants lose E3 activity, but act as adaptors that gain function to cause myeloproliferative neoplasms. Currently, there is no targeted treatment available for patients with CBL mutant-dependent disorders. By combining phage-display technology and structure-based optimization, we discovered CBLock, a nanomolar affinity peptide inhibitor, that binds the substrate-binding site of CBL's tyrosine kinase binding domain (TKBD). CBLock disrupts the interaction between CBL mutants and RTKs, thereby impairing RTK-mediated priming of adaptor function of CBL mutants and downstream signaling. Notably, CBLock binds TKBD without inducing conformational changes, thereby preserving its ligand-free native conformation. In contrast, when CBL binds RTK substrates, TKBD undergoes a conformational change. Maintaining the native CBL TKBD conformation was crucial for CBLock to inhibit proliferation, induce cell-cycle arrest, and promote apoptosis in leukemia cells harboring CBL mutations. In a mouse xenograft model of acute myeloid leukemia (AML), CBLock reduced tumor burden and improved survival rate. Moreover, CBLock inhibited the proliferation of cells derived from patients with CBL mutations. Therefore, inhibiting CBL TKBD in its native state presents a promising therapeutic opportunity in targeting mutant CBL-dependent leukemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-cblMutationLeukemia, Myeloid, AcuteHumansAnimalsMiceCell Line, TumorProtein BindingXenograft Model Antitumor AssaysProtein ConformationApoptosisBinding SitesCell ProliferationSignal TransductionDisease Models, Animal

Stichwörter der Autor:innen

AMLCBLCBL TKBDCBL inhibitorCBL mutantsE3 ligaseRTKpeptide inhibitorphage-display

Substanzen

Proto-Oncogene Proteins c-cblCBL protein, human

Autor:innen und Institutionen

  • Cancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
  • Department of Molecular and Cellular Biology, College of Biological Science, University of Guelph, 50 Stone Road E, Guelph, ON N1G2W1, Canada.
  • Laboratory of Human Genetics of Infectious Diseases, Necker Hospital for Sick Children, 75015 Paris, France; Paris Cité University, Imagine Institute, 75015 Paris, France.
  • Cancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK; School of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
  • School of Pharmacy, University of Waterloo, 10 Victoria Street S A, Kitchener, ON N2G1C5, Canada.
  • Cancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK; School of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK. Electronic address: d.huang@crukscotlandinstitute.ac.u…

Förderung

  • European Research Council
  • Glasgow Children's Hospital Charity
  • Cancer Research UK Beatson Institute
  • Cancer Research UK
  • Genome Canada
  • Horizon 2020 Framework Programme

Zitieren

APA

Ahmed, S. F., Anand, J., Zhang, W., Buetow, L., Rishi, L., Mitchell, L., Bohlen, J., Lilla, S., Sibbet, G. J., Nixon, C., Patel, A., Majorek, K. A., Zanivan, S., Bustamante, J. C., Sidhu, S. S., Blyth, K., & Huang, D. T. (2025). Locking CBL TKBD in its native conformation presents a novel therapeutic opportunity in mutant CBL-dependent leukemia. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.04.042

Vancouver

Ahmed SF, Anand J, Zhang W, Buetow L, Rishi L, Mitchell L, et al. Locking CBL TKBD in its native conformation presents a novel therapeutic opportunity in mutant CBL-dependent leukemia. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.04.042

BibTeX
@article{Ahmed2025,
  author = {Ahmed, Syed Feroj and Anand, Jayanthi and Zhang, Wei and Buetow, Lori and Rishi, Loveena and Mitchell, Louise and Bohlen, Jonathan and Lilla, Sergio and Sibbet, Gary J and Nixon, Colin and Patel, Amrita and Majorek, Karolina A and Zanivan, Sara and Bustamante, Jacinta C and Sidhu, Sachdev S and Blyth, Karen and Huang, Danny T},
  title = {Locking CBL TKBD in its native conformation presents a novel therapeutic opportunity in mutant CBL-dependent leukemia},
  journal = {Molecular Therapy},
  year = {2025},
  doi = {10.1016/j.ymthe.2025.04.042}
}
Kostenlos starten →